Full-Time

Director – Oligonucleotide CMC

Confirmed live in the last 24 hours

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech

You match the following Tessera Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • PhD or MS in relevant field with 10+ years of experience in the biopharmaceutical industry
  • Expertise in oligonucleotide synthesis, scale-up, and purification process
  • Leveraging in-process analytical characterization methods, CPP, CQAs etc. to assure robust scalable manufacturing control
  • Managing external development or technology transfer of synthesis and purification methods
  • Tracking record of manufacturing per GMP requirements, including the engagement of CRO and CDMO capabilities
  • Authoring of relevant CMC sections of IND, NDA/BLA and other regulatory filings related to oligonucleotide therapeutics
  • Driving novel oligonucleotide chemistry and processes to improve research candidates
  • Strong organizational leadership skills with a proven track record in managing programs and cross-functional development teams
  • Excellent written and presentation skills
Responsibilities
  • Defining and optimizing oligonucleotide process and analytical control strategies and managing project timelines, budget and development teams
  • Leading external manufacturing of oligonucleotides with CMOs to support GLP tox studies and IND submissions
  • Independently leading both internal team and external CRO partners
  • Mentoring and coaching junior scientists
  • Working effectively with a cross-functional and highly collaborative biology, technology, and chemistry team to contribute to the delivery of key organizational goals/milestones
Desired Qualifications
  • Prior experience with long oligos via chemical or enzymatic synthesis routes is very desirable

Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company primarily serves research institutions, pharmaceutical companies, and healthcare providers seeking to develop new treatments for genetic diseases. Unlike its competitors, Tessera emphasizes the versatility of its technology and its potential to address previously untreatable conditions. The goal of Tessera Therapeutics is to advance genetic medicine by rewriting the genetic code to cure diseases.

Company Size

201-500

Company Stage

Series C

Total Funding

$518.2M

Headquarters

Cambridge, Massachusetts

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Gates Foundation boosts development of sickle cell disease treatment.
  • $300 million Series C funding in 2022 supports platform advancement and commercialization.
  • Located in Boston, Tessera benefits from a thriving biotech ecosystem.

What critics are saying

  • Competition from CRISPR-based technologies may challenge Tessera's market position.
  • High development costs could delay Gene Writing technology's market entry.
  • Regulatory hurdles may slow approval and adoption of genetic therapies.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics pioneers Gene Writing, a novel approach in genetic medicine.
  • Their technology allows precise genome alterations, surpassing traditional gene editing methods.
  • Tessera's platform targets a wide range of genetic disorders with versatile applications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

0%
DDW Online
Dec 18th, 2024
Investment to develop curative in vivo genetic treatment for sickle cell disease

Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company's in vivo programme for sickle cell disease (SCD).

BioSpace
Dec 18th, 2024
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Tessera is developing Gene Writers(TM) for SCD designed to enable a true correction of the sickle mutation to wild-type with one-time intravenous administration in vivo, without the need for complex stem cell mobilization or toxic chemotherapy conditioning.

The Manila Times
Dec 18th, 2024
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Tessera Therapeutics receives investment to develop curative in vivo genetic treatment for sickle cell disease.

Bizjournals
Dec 18th, 2024
Gates Foundation invests $50M in Tessera

The Bill & Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support its development of in-vivo genetic medicines for sickle cell disease. Tessera aims to offer a one-time intravenous treatment that avoids the need for high-dose chemotherapy and complex stem cell mobilization, unlike existing ex-vivo therapies. Tessera, founded by Flagship Pioneering, previously raised $230 million in Series B financing in 2021 and $300 million in 2022.

Labiotech
Oct 10th, 2024
12 Biotech Unicorns Revolutionizing The Future Of Healthcare

Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing

CGT Live
Aug 1st, 2024
Michael Severino on In Vivo Gene Editing With RNA Gene Writers

The chief executive officer of Tessera Therapeutics discussed ongoing research into developing its platform for sickle cell disease, CAR T-cell therapy, and more.

Business Wire
May 6th, 2024
Xperi Director Who Served With Dissident Nominee Tom Lacey Encourages Xperi Stockholders To Vote For All Of The Board'S Candidates At The 2024 Annual Meeting

SAN JOSE, Calif.--(BUSINESS WIRE)--Xperi Inc. (NYSE: XPER) (the “Company” or “Xperi”), an entertainment technology company that invents, develops and delivers technologies that enable extraordinary experiences, today publicized a letter written by one of its directors who is not being targeted by activist stockholder Rubric Capital, Christopher Seams. Mr. Seams served on the board of one of Xperi’s predecessors while one of Rubric’s nominees, Thomas Lacey, was CEO of that predecessor company. In the letter, Mr. Seams expresses his support for the targeted directors, highlights their contributions to Xperi’s multi-year transformation and contrasts their expertise in software development, technology, audio-visual technologies and content monetization with Rubric’s nominees’ lack of experience in these critical areas

Labiotech
Mar 12th, 2024
The Twelve Hottest Biotech Companies In The Boston Area

The Boston region in the U.S. state of Massachusetts (MA) hosts one of the leading biotech hubs in the world, ranking second just in front of the BioHealth Capital Region. Here are twelve of Boston’s most innovative biotech companies.The Boston region has sprouted many influential public biotech companies. One of the most successful in recent years was Moderna, a giant messenger RNA (mRNA) specialist incubated by the VC firm Flagship Pioneering. Moderna would go on to produce one of the first COVID-19 vaccines in 2020. Another prestigious name, Vertex Pharmaceuticals, one of the 14 biotechs with a market capitalization above $100 billion, is also headquartered in Boston.The Boston hub shows few signs of slowing down, and there is a host of biotech companies generating excitement among investors.Table of contentsAkouosAkouos, founded in 2016 focuses on developing gene therapies for hearing loss

Endpoints News
Jul 12th, 2023
San diego biotech se­cures $75M to ad­vance lead can­di­date

Arthrosi Ther­a­peu­tics, a biotech com­pa­ny de­vel­op­ing a gout treat­ment, raised a fresh $75 mil­lion through a Se­ries D round.

BioSpace
May 19th, 2023
Tessera Therapeutics Presents New Data Demonstrating The Potential Of Gene Writing™ Technology At The American Society Of Gene And Cell Therapy 26Th Annual Meeting

RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency (AATD) and sickle cell disease (SCD) including proof of concept in non-human primates (NHPs) for PKU. RNA Gene Writing™ technology enables multiplexed full-length gene writing and rewriting with RNA-only delivery to engineer CAR-T cells with robust antitumor activity. Proprietary lipid nanoparticle (LNP) delivery demonstrates potential to effectively reach cell types beyond hepatocytes including hematopoietic stem cells (HSCs) and T cells